SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Lorraine Hansberry — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLorraine Hansberry
Date of birth1930-05-19
IdentifiersMRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158
Document date1963-05-04
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis visit: biopsy results, the tumor board plan, and the oncology consultation. [S]

History of Present Illness

Ms. Hansberry returns two weeks after her first visit. Upper endoscopy two days after that visit found no ulcer but an ulcerated mass in the duodenum next to the papilla, oozing slowly, and the biopsies show adenocarcinoma. The pancreas-protocol CT the next day showed a 3.1 cm mass in the head of the pancreas invading the duodenum, with dilated bile and pancreatic ducts and contact with more than half the circumference of the superior mesenteric vein, but no contact with the arteries and no spread to the liver, peritoneum or lungs. Endoscopic ultrasound a week ago confirmed pancreatic adenocarcinoma on biopsy, and a metal stent was placed in the bile duct at the same session; her urine is lighter and the itching has gone. The tumor board reviewed her five days ago. She had two doses of intravenous iron and has had no more black stools. Pain in the upper abdomen and back is 6 out of 10 and wakes her. Her stools are pale and float after fatty meals. She saw Dr. Adeyemi-Rourke this morning and genetic counseling this afternoon. She asked to be told everything plainly and was. She has had no thoughts of self-harm. [S]

ElementDetail
DiagnosisAdenocarcinoma of the head of the pancreas invading the duodenum; borderline resectable (venous contact more than 180 degrees, no arterial contact); no distant spread
Procedures since the first visitUpper endoscopy with biopsy; pancreas-protocol CT; EUS-guided biopsy; ERCP with a metal biliary stent; two doses of intravenous iron
Tumor boardModified FOLFIRINOX before surgery, restaging, then resection if no progression
SymptomsPain 6 out of 10; pale floating stools; no more black stools; itching gone
Her questionsWhether this can be cured; whether she can keep writing; what the genetic test means for her family; whether she could still have children

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; weight 55.4 kg, down 0.8 kg in two weeks; no fever
GastrointestinalPositiveUpper abdominal and back pain; pale, floating stools after fatty meals; no black stools since the iron; nausea mild
IntegumentaryNegativeItching gone after the stent; no rash
CardiovascularNegativeNo more near-fainting; no leg swelling
GenitourinaryNegativeUrine lighter; last period two weeks ago
PsychiatricPositiveShaken by the diagnosis and determined; PHQ-9 7, GAD-7 8; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route1963-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route1963-04-24 to 1963-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route1963-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route1963-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route1963-05-04 to 1963-10-05completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1963-05-04Body height163cmS
1963-05-04Body weight55.4kgS
1963-05-04Body mass index (BMI) [Ratio]20.9kg/m2S
1963-05-04Systolic blood pressure108mm[Hg]S
1963-05-04Diastolic blood pressure68mm[Hg]S
1963-05-04Heart rate92/minS
1963-05-04Respiratory rate16/minS
1963-05-04Body temperature36.7CelS
1963-05-04Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1963-05-04Hemoglobin [Mass/volume] in Blood10.4g/dL12-15.5 g/dLLowS
1963-05-04Leukocytes [#/volume] in Blood by Automated count710*3/uL4-11 10*3/uLNormalS
1963-05-04Neutrophils [#/volume] in Blood by Automated count4.610*3/uL1.5-7.7 10*3/uLNormalS
1963-05-04Platelets [#/volume] in Blood by Automated count36610*3/uL150-400 10*3/uLNormalS
1963-05-04Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
1963-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M119mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1963-05-04Glucose [Mass/volume] in Serum or Plasma141mg/dL70-99 mg/dLHighS
1963-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-35 U/LNormalS
1963-05-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L8-35 U/LNormalS
1963-05-04Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma168U/L35-104 U/LHighS
1963-05-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.1-1.2 mg/dLNormalS
1963-05-04Albumin [Mass/volume] in Serum or Plasma3.5g/dL3.5-5 g/dLNormalS
1963-05-04Cancer Ag 19-9 [Units/volume] in Serum or Plasma486U/mL<=35 U/mLHighS
1963-05-04Carcinoembryonic Ag [Mass/volume] in Serum or Plasma3.9ng/mLUp to 3.0 ng/mL in non-smokersHighS
1963-05-04INR in Platelet poor plasma by Coagulation assay1{INR}0.8-1.2NormalS
1963-05-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1963-05-04Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1963-05-04Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S

Physical Exam

Vital signs recorded on 1963-05-04; see the Vital Signs section. [S]

SystemFinding
GeneralThin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92
EyesSlight scleral icterus, less than at the first visit
AbdomenTender in the epigastrium without guarding; no mass felt; no liver enlargement; no ascites
Lymph nodesNo supraclavicular nodes; no umbilical nodule
ExtremitiesNo calf tenderness or leg swelling
PsychiatricDirect, asks exact questions, writes down the answers; tearful briefly

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPactiveconfirmed K83.1S — Synthetic consequence of the synthetic tumor.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryTissue diagnosisBefore treatmentUp to dateEUS-guided biopsy: adenocarcinoma of the pancreas, moderately differentiated; duodenal biopsies: adenocarcinoma invading from the pancreas
ImagingPancreas-protocol CT of the abdomen with CT of the chestAt diagnosis, before any treatmentUp to dateBorderline resectable: superior mesenteric vein contact about 200 degrees with reconstructible narrowing; no arterial contact; no metastases
ReferralPancreatic multidisciplinary tumor boardBefore treatment for every localized pancreatic cancerUp to dateFive days ago: modified FOLFIRINOX first, restaging, then resection
LaboratoryBiliary drainage and liver testsBefore chemotherapy when the bile duct is blockedCompleted todayMetal stent placed a week ago; bilirubin 0.9 mg/dL (from 1.6), alkaline phosphatase 168 U/L, ALT 30 U/L, AST 28 U/L, albumin 3.5 g/dL
LaboratoryCA 19-9At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six monthsCompleted today486 U/mL, drawn after biliary drainage so that it is not falsely raised by jaundice; CEA 3.9 ng/mL
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycle and at each visitCompleted todayHemoglobin 10.4 g/dL, white cells 7.0, neutrophils 4.6, platelets 366
LaboratoryKidney function before chemotherapyBefore each cycleCompleted todayCreatinine 0.68 mg/dL, eGFR 119
LaboratoryINR before port placementBefore the procedureCompleted today1.0
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore chemotherapyOrderedHepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today
LaboratoryPregnancy testBefore chemotherapyCompleted todayUrine pregnancy test negative
ReferralGenetic counselingAt diagnosis of pancreatic cancerCompleted todayPedigree taken; no known pancreatic, breast, ovarian, prostate or colorectal cancer in her family; consent given
LaboratoryGermline multigene panelOnce, at diagnosis, for every patient with pancreatic cancerOrderedIncludes BRCA1, BRCA2, PALB2, ATM, CDKN2A, the Lynch syndrome genes, STK11 and TP53; result in about three weeks
LaboratoryTumor molecular profilingAt diagnosis, on tissueOrderedNext-generation sequencing on the EUS cores, with mismatch repair status and fusion testing
ReferralFertility counselingBefore gonadotoxic chemotherapyCompleted todayOxaliplatin and irinotecan may reduce fertility. Egg or embryo freezing would delay chemotherapy by about two weeks; she chose not to delay treatment, which was respected. Effective non-estrogen contraception advised
ReferralPalliative careFrom diagnosis, alongside cancer treatmentReferredOutpatient palliative care consultation in two days
SurveyPain score and opioid reviewEach visitCompleted todayPain 6 out of 10; oxycodone 5 mg as needed started with senna
Self-managementWeight, nutrition and enzyme replacementEach visitCompleted todayWeight 55.4 kg; pancrelipase started; dietitian referral this week
LaboratoryGlucose and home readingsEach visit and before each cycleCompleted todayFasting glucose 141 mg/dL: with the A1c of 6.6%, diabetes is confirmed
ExaminationDilated eye examination and urine albumin-to-creatinine ratioAt diagnosis of diabetes, then yearlyDueTo be arranged now that diabetes is confirmed
Medication safetyVenous thromboembolism risk (Khorana score)At the start of chemotherapyCompleted todayKhorana score 3 (pancreatic primary, hemoglobin under 10 g/dL at the first visit). Primary prophylaxis with apixaban is recommended for this score, but it is held for now because the duodenal tumor bled within the last month; to start when there has been no bleeding for several weeks
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 7 and GAD-7 8, mild, with fear about the diagnosis; no thoughts of self-harm
Self-managementPlain information and support she choosesAt diagnosis and throughoutCompleted todayPlain explanation of the diagnosis, its stage and the aim of treatment, with written information; she chose who would be told and who receives her notes

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before chemotherapy; Recombinant zoster vaccine, dose 1 of 2, before chemotherapy [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020); Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Noel M, Fiscella K. Disparities in Pancreatic Cancer Treatment and Outcomes. Health Equity 2019;3(1):532-540 (PMID 31663065) (2019); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Palliative care in two days; port next week; cycle 1 in two weeks. Primary care review at cycle 4. Call at once for fever, yellow eyes, black stools, fainting, or leg swelling. Next scheduled visit 1963-06-29: day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood. [S]